Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The objective of this study was to examine the effect of cochlear dose on hearing preservation in stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) for vestibular schwannoma (VS). This is a retrospective case-control study. This study was completed at the Ronald Reagan UCLA Medical Center, a university-affiliated tertiary care center. Patients who underwent SRS (marginal dose of 12 Gy) or fSRT (marginal dose of 50.4 Gy) procedures for VS were included in the study. The main outcome measure was hearing preservation. Audiometric data, when available, were used to determine the level of hearing according to the Gardner Robertson scale. A total of 38 patients (14 SRS and 24 fSRT) were analyzed. SRS patients with decreased hearing received a significantly higher minimum cochlear dose (7.41 vs. 4.24 Gy, = 0.02) as compared with those with stable hearing. In fSRT patients, there were no significant differences in cochlear dose for patients with decreased hearing as compared with those with stable hearing. For SRS patients, who received a minimum cochlear dose above 6 Gy, there was a significant risk of decreased hearing preservation (odds ratio: 32, = 0.02). Higher minimum cochlear dose was predictive of decreased hearing preservation following SRS. Though the study is low powered, the radiation dose to the cochlea should be a parameter that is considered when planning SRS or fSRT therapies for patients with VS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043171 | PMC |
| http://dx.doi.org/10.1055/s-0037-1607968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Magnetic Targeting of AAV Gene Therapy for Inner Ear Following Systemic Delivery: Preliminary Findings and Transduction Pattern in Rat Cochlea.
J Assoc Res Otolaryngol
September 2025
Biological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Room M1 102, Toronto, ON, M4N 3M5, Canada.
Purpose: Delivery of therapeutics to the inner ear is complicated by their inaccessible location and the presence of the blood-labyrinth barrier that restricts most blood-borne compounds from entering the inner ear. This study addresses the challenge of optimal delivery in treating inner ear disease, focusing on magnetic targeting gene therapy using adeno-associated virus (AAV).
Methods: The investigation explores three AAV serotypes (AAV2 Quad Mut, AAV2 pANC80L65, and AAV9 PHP.
Early Markers of Sensorineural Hearing Loss After Platinum-Based Chemotherapy.
Ear Hear
September 2025
Department of Information Technology - Hearing Technology @Waves, Ghent University, Ghent, Belgium.
Objectives: Platinum-based chemotherapy, cisplatin as well as carboplatin, can cause ototoxicity, which refers to drug-related damage affecting inner ear structures. At present, most ototoxicity monitoring programs rely on pure-tone audiometry, which is inadequate for detecting early outer hair cell (OHC) damage. Recent animal studies have shown that platinum derivatives can damage auditory nerve fibers (ANF), leading to cochlear synaptopathy (CS).
View Article and Find Full Text PDFEthacrynic acid regulates gentamicin ototoxicity via the blood-labyrinth barrier.
Hear Res
August 2025
Department of Otolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guang Zhou, Guangdong, China, 510630. Electronic address:
Gentamicin (GM), a widely used aminoglycoside antibiotic, has its clinical utility significantly limited by ototoxicity, which may be further exacerbated by co-administered drugs. This study systematically investigated the ototoxic mechanisms of GM combined with ethacrynic acid (EA) and the protective effects of N-acetylcysteine (NAC) using C57BL/6 J mice. Results revealed dose-dependent GM-induced ototoxicity.
View Article and Find Full Text PDFRound window membrane extracellular vesicles facilitate inner ear drug delivery.
J Control Release
August 2025
Department of Biomedical Engineering, North Carolina State University, Raleigh, NC, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:
Over 400 million people are affected by hearing loss, but currently the promising treatments remain limited in part due to challenges of inner ear drug delivery, which is risky, variable, and not efficient. To improve clinical treatments for hearing loss, a safe, reliable, and effective local delivery system is needed to ensure the therapeutic dose reaches the inner ear. Intratympanic (IT) injection is currently the safest method, preserving cochlear integrity, but has low efficiency due to the presence of the round window membrane (RWM), gatekeeper of the inner ear equipped with tight junctions, limiting therapy-related substance passage.
View Article and Find Full Text PDFHistamine H3 Receptor Antagonists Influence the Directional Growth of Type II Spiral Ganglion Neurites Within the Developing Cochlea of C57BL/6 Mice.
Neurochem Res
August 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany.
The histamine H3 receptor (H3R) is a crucial regulator of synaptic plasticity, neurotransmitter release, and neural signaling within the central nervous system. However, its role in the cochlea remains poorly understood, even though mast cells, a rich endogenous source of histamine, have recently been documented in the mammalian cochlea. This study examined H3R expression and localization in the postnatal day 4-5 (P4-5) C57BL/6 mouse cochlea and evaluated its functional consequences under antagonist treatment.
View Article and Find Full Text PDF